KALA BIO, Inc 8-K, filed Nov 16, 2026
KALA BIO, Inc. (KALA)
About this 8-K
KALA BIO, Inc filed this 8-K on November 16, 2026, reporting on events of November 13, 2026.
Nasdaq granted KALA BIO, Inc. continued listing on The Nasdaq Capital Market, requiring a closing bid price of at least $1.00 per share from November 30, 2026 through February 23, 2027. The company had received a bid-price deficiency notice for July 16, 2026 through August 26, 2026. AI summary
Items reported
- Item 8.01: Other events
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in its Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
||
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code:
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Items.
On August 27, 2026, KALA BIO, Inc. (the “Company”) received a letter (the “Staff Determination Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff has determined that the closing bid price of the Company’s common stock, par value $0.001 per share (the “Common Stock”), has been below $1.00 per share for the previous 30 consecutive business days (from July 16, 2026 through August 26, 2026) and, as a result, the Company is not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(2).
On October 6, 2026, the Company met with the Nasdaq Hearings Panel (the “Panel”). On November 13, 2026, the Panel granted the Company’s request to continue its listing on Nasdaq subject to the following conditions: (i) the Company shall evidence a closing bid price of at least $1.00 per share for ten consecutive business days by November 30, 2026; (ii) the Company must maintain a closing bid price of at least $1.00 for each trading day after November 30, 2026 until February 23, 2027; and (iii) if the Company becomes non-compliant with any other Nasdaq listing rule prior to February 23, 2027, the Company will be allowed seven days to advise the Panel on the Company’s plan to cure the listing deficiency and the Panel shall determine whether to grant the Company an exception to cure the deficiency or delist the Company. If the Company maintains compliance until February 23, 2027, the Panel intends to impose a discretionary monitor for the next year. The Panel has reserved the right to reconsider its decision based on any event, condition or circumstance that exists or develops that would, in the opinion of the Panel, make continued listing of the Common Stock on Nasdaq inadvisable or unwarranted.
There can be no assurance that the Company will be able meet the Panel’s conditions or maintain compliance with the requirements for continued listing on The Nasdaq Capital Market.
Forward-Looking Statements
This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding the Company’s ability to meet the Panel’s condition and its future maintenance of compliance with the Nasdaq continued listing requirements. Forward-looking statements are subject to a number of risks and uncertainties, including that the Company may not be able to satisfy the Panel’s conditions and other risks and uncertainties set forth from time to time in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| KALA BIO, INC. | ||
| Date: November 16, 2026 | By: | /s/ Avi Minkowitz |
| Avi Minkowitz | ||
| Chief Executive Officer | ||
2